CoChat

Point: Postprandial Glucose Levels Are a Clinically Important Treatment Target

Open access
Ceriello, Antonio · 2010 · Diabetes Care
Cited by 49

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

The results of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial have been recently reported (1–2). Nateglinide, a member of the meglitinide class, which has been shown to lower postprandial hyperglycemia by increasing the first phase of insulin secretion, was not effective in decreasing both the new cases of diabetes and the new cardiovascular events in a population at high risk (1). Valsartan, an angiotensin (AT-1) blocker, was ineffective on cardiovascular events but significantly—even marginally—reduced the onset of new diabetes (2). The negative results of nateglinide immediately raised the concern about the possibility that postprandial hyperglycemia could be considered an independent risk factor for cardiovascular disease (CVD) and whether its treatment may give any advantage in the management of diabetes (3). Diabetologists have long debated whether the lack of insulin action (insulin resistance) or impaired insulin secretion represents the primary pathological mechanism underlying type 2 diabetes. Recent analyses confirm that impaired pancreatic β-cell glucose sensitivity and whole-body insulin sensitivity are strong predictors of a progression to hyperglycemia (4). Conversely, numerous studies have shown that acute insulin secretion defects represent a powerful early predictor of diabetes progression. During the progression from normal glucose tolerance to increasingly severe type 2 diabetes, first-phase insulin secretion (FPIS) is an early casualty. Prior to the diagnosis of diabetes, insulin response to mealtime glucose becomes delayed and blunted; eventually, it is lost (5). In a landmark study, Polonsky et al. (5) showed that FPIS responses were more sluggish and less dramatic in diabetic individuals. In another analysis, a marked and increasing loss of the early-phase β-cell secretory response to a meal challenge correlated with increasing postprandial hyperglycemia in a group of individuals recently diagnosed with diabetes (6). Together these data indicate that declining FPIS and postprandial hyperglycemia are key …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc10-0634

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 49

Metadata

Authors
Ceriello, A.
Venue
Diabetes Care
Published
2010-08-01
Volume
33
Issue
8
Pages
1905-1907
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2076205364
Cited by
49
References
13
FWCI
2.42
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.